Burleson Research Technologies has partnered with SenzaGen in an agreement to market and offer the in vitro GARD test method, making BRT the first U.S. laboratory to offer this service. The GARD method displays a higher accuracy than other available methods and reveals if chemical substances are causing allergies in humans.
“We are looking forward to providing our customers access to the GARD tests – a robust animal-free test with high accuracy that has the potential to become a widely used method for characterizing allergy-provoking properties of chemical substances. Our experiences from participating in the successful validation trial show that the test is both reliable and easy to perform”, says Gary Burleson, CEO of Burleson Research Technologies.
